Lactobacillus GG + mesalazine

Lactobacillus GG + mesalazine is a combination therapy used primarily for treating ulcerative colitis (UC), a type of inflammatory bowel disease (IBD). This combination brings together the anti-inflammatory properties of mesalazine with the probiotic benefits of Lactobacillus GG. ## Mechanism of Action The combination works through complementary mechanisms: 1. **Mesalazine (5-ASA)** acts as an anti-inflammatory agent that works locally in the intestinal mucosa to reduce inflammation in the colon[8]. It's a standard treatment for ulcerative colitis that helps maintain remission and treat active disease. 2. **Lactobacillus GG** is a probiotic strain that helps restore beneficial gut bacteria, potentially improving immune function and reducing inflammation[2][4]. It appears to work by: - Supporting intestinal barrier function - Modulating immune responses - Competing with harmful bacteria - Producing beneficial metabolites ## Clinical Efficacy Research shows that Lactobacillus GG combined with mesalazine may be more effective than mesalazine alone for treating ulcerative colitis: - The combination therapy has demonstrated higher clinical remission rates compared to mesalazine monotherapy[7]. - Lactobacillus GG appears to be effective in prolonging relapse-free time compared to standard mesalazine treatment[2]. - The combination can substantially improve disease conditions in IBD patients by enhancing immune function and reducing inflammation levels[1]. ## Dosage and Administration Based on clinical studies, typical dosing includes: - **Mesalazine**: 2400 mg daily (often divided into multiple doses)[2] - **Lactobacillus GG**: 18 × 10^9 viable bacteria daily[2] The combination is typically administered orally, with specific dosing regimens varying based on disease severity and patient factors. ## Safety Profile The combination therapy appears to have a good safety profile: - No significant difference in the incidence of adverse reactions compared to mesalazine alone[1] - Lactobacillus GG is generally well-tolerated, with only minor side effects like gas and bloating reported in some patients[4] - Caution is advised for immunocompromised individuals, as there's a potential risk of infections with probiotic use[4] ## Clinical Applications The primary uses for Lactobacillus GG + mesalazine include: 1. **Treatment of active ulcerative colitis** - particularly mild to moderate cases 2. **Maintenance of remission** in ulcerative colitis patients 3. **Reduction of inflammation** and improvement of immune function in IBD patients Some studies suggest this combination may be particularly beneficial for preventing relapse in patients with quiescent ulcerative colitis[2][3]. ## Future Directions While current evidence supports the use of this combination therapy, additional research is needed to: - Determine optimal dosing regimens - Identify patient populations most likely to benefit - Evaluate long-term safety and efficacy - Explore potential applications in other inflammatory conditions The combination of Lactobacillus GG and mesalazine represents a promising approach that leverages both conventional anti-inflammatory medication and microbiome-based therapy for managing inflammatory bowel disease.